1. Medtech Insight

The Case For Disappearing Stents: More Positive Data For Abbott’s Absorb BVS

This year’s Transcatheter Cardiovascular Therapeutics meeting featured several presentations of favorable new data on Abbott’s Absorb bioresorbable vascular scaffold. The company is optimistic that it will be able to complete a PMA application to FDA for the disappearing stent by the end of 2015.

Abbott Laboratories Inc. ’s Absorb everolimus-eluting bioresorbable vascular scaffold(BVS) remains on track for a late-2015 PMA submission based on data showing the novel device performed at least as well as the company’s Xience everolimus-eluting metal stent at the one-year follow-up of the first randomized controlled trial for the dissolving coronary stent.

One-year results from 501 patients in the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight